Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
Patients with HER2-low breast cancer have longer survivals yet display no differences in immune-related gene expression when compared to those with HER2-zero cancers. The differences in survival can be attributed to the higher rate of ER-positivity seen in HER2-low breast cancers, compared to HER2-zero tumors.
Authors
- Taylor J. Jensen (ORCID: https://orcid.org/0000-0002-7206-7656)
- Stephanie B. Hastings
- Eric A. Severson (ORCID: https://orcid.org/0000-0003-4394-2412)
- Jeffrey M. Conroy (ORCID: https://orcid.org/0000-0003-1764-9706)
- Marcia Eisenberg
- Erik Van Roey
- Shengle Zhang
- Shipra Gandhi (ORCID: https://orcid.org/0000-0003-3506-0284)
- R. J. Seager (ORCID: https://orcid.org/0000-0002-2866-5288)
- Sarabjot Pabla (ORCID: https://orcid.org/0000-0002-7746-9144)
- Rebecca A. Previs (ORCID: https://orcid.org/0000-0001-8087-9120)
- Brian Caveney
- Mary Nesline (ORCID: https://orcid.org/0000-0003-0523-4597)
- Shakti Ramkissoon
- Heidi Ko (ORCID: https://orcid.org/0000-0002-7247-9175)
- Kyle C. Strickland (ORCID: https://orcid.org/0000-0003-1636-5277)
- Maria-Fernanda Senosain (ORCID: https://orcid.org/0000-0002-3933-7167)
- Michelle Green (ORCID: https://orcid.org/0000-0002-6055-4342)
- Shuang Gao (ORCID: https://orcid.org/0000-0002-6360-3533)
- Maureen Cooper
- Kobina Agyaful Amoah
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- LabCorp (United States) (US)
- Duke Medical Center (US)
- Wake Forest University (US)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/bctt.s476394
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.41